Opsumit (macitentan)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

June 2016

ADVERSE REACTIONS

Postmarketing Experience

Cardiac disorders: symptomatic hypotension (addition)

...

Source: Drugs.com - Labeling Changes - June 1, 2016 Category: Drugs & Pharmacology Source Type: alerts